Anyone who has ever snapped a spoke on their bike or broken down with their car knows that mechanical stresses sooner or later result in damage that needs to be repaired. This also applies to the human musculature. "With each movement, structural proteins are damaged and have to be replaced," explains adjunct professor Dr. Michael Hesse from the Institute of Physiology at the University of Bonn, who led the study together with his colleague Prof. Dr. Bernd Fleischmann.
The defective molecules are normally broken down in the cell and their components are then recycled. An important role in this complex process is played by a protein called BAG3. The results of the new study show how important this is: The researchers were able to demonstrate that a single change in the genetic blueprint of BAG3 results in a fatal disease.
"The mutation causes BAG3 to form insoluble complexes with partner proteins that grow larger and larger," Hesse says. This brings the repair processes to a standstill - the muscles become less and less efficient. Moreover, toxic levels of proteins accumulate over time, eventually resulting in the death of the muscle cell. "The consequences are usually first seen in the heart," Hesse says. "There, muscle is successively replaced by scar tissue. This causes the heart's elasticity to decrease until it can barely pump blood."
Affected individuals therefore usually require a heart transplant in childhood. Even this measure only provides temporary relief, as the disease also affects the skeletal and respiratory muscles. As a result, sufferers often die at a young age.
Very rare condition, therefore little research
The lethal mutation can arise spontaneously during embryo development. Fortunately, this is a very rare occurrence: There are probably only a few hundred affected children worldwide. However, due to its rarity, the disease has received little research attention to date. "Our study now takes us a great deal further," stresses Bernd Fleischmann.
This is because the researchers have succeeded for the first time in replicating the disease in mice and using the new animal model to identify its causes. This allows it to be researched better than before - also with regard to possible therapies. Maybe the effect of the mutation can at least be reduced. Humans have two versions of each gene, one from the mother and the other from the father. This means that even if one version of BAG3 mutates during embryo development, there is still a second gene that is intact.
Unfortunately, however, the defective BAG3 also clumps with its intact siblings. The mutation in one of the genes is therefore sufficient to stop the breakdown of the defective muscle proteins. However, if the mutated version could be eliminated, the repair should work again. It would also prevent the massive accumulation of proteins in the cell that eventually results in its death.
There are indeed methods to specifically inhibit the activity of individual genes. "We used one of them to treat the sick mice," explains Kathrin Graf-Riesen of the Institute of Physiology, who was responsible for most of the experiments along with Dr. Kenichi Kimura and her colleague Dr. Astrid Ooms. The animals treated in this way then showed significantly fewer symptoms. Whether this approach can be transferred to humans, however, remains the subject of further research.
Participating institutions and funding:
In addition to the Institute of Physiology I, the Institute for Cell Biology of the University of Bonn and the Clinic for Cardiac Surgery of the University Hospital Bonn were involved in the study. The partners also include Forschungszentrum Jülich, the Universities of Münster, Freiburg and Cologne, as well as Stanford University in the USA and the University of Tsukuba in Japan. The study was funded by the German Research Foundation (DFG), including the research group "Mechanical Stress Protection".
Publication: Kenichi Kimura et al: Overexpression of human BAG3P209L in mice causes restrictive cardiomyopathy. Nature Communications, https://doi.org/10.1038/s41467-021-23858-7
